Overview

Treatment of Anemia in Diabetic Subjects With CKD

Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline by Week 17.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator:
Ortho Biotech Products, L.P.
Treatments:
Epoetin Alfa